Trade-Ideas LLC identified

Biomarin Pharmaceutical

(

BMRN

) as a post-market laggard candidate. In addition to specific proprietary factors, Trade-Ideas identified Biomarin Pharmaceutical as such a stock due to the following factors:

  • BMRN has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $140.6 million.
  • BMRN is down 4.8% today from today's close.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in BMRN with the Ticky from Trade-Ideas. See the FREE profile for BMRN NOW at Trade-Ideas

More details on BMRN:

BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Currently there are 11 analysts that rate Biomarin Pharmaceutical a buy, no analysts rate it a sell, and 3 rate it a hold.

The average volume for Biomarin Pharmaceutical has been 1.7 million shares per day over the past 30 days. Biomarin has a market cap of $12.2 billion and is part of the health care sector and drugs industry. The stock has a beta of 1.80 and a short float of 4.5% with 3.09 days to cover. Shares are down 27.1% year-to-date as of the close of trading on Wednesday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates Biomarin Pharmaceutical as a

sell

. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity and generally disappointing historical performance in the stock itself.

Highlights from the ratings report include:

  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Biotechnology industry. The net income has significantly decreased by 1321.3% when compared to the same quarter one year ago, falling from $7.45 million to -$90.93 million.
  • Current return on equity is lower than its ROE from the same quarter one year prior. This is a clear sign of weakness within the company. Compared to other companies in the Biotechnology industry and the overall market, BIOMARIN PHARMACEUTICAL INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • Despite any intermediate fluctuations, we have only bad news to report on this stock's performance over the last year: it has tumbled by 27.57%, worse than the S&P 500's performance. Consistent with the plunge in the stock price, the company's earnings per share are down 1300.00% compared to the year-earlier quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.
  • The gross profit margin for BIOMARIN PHARMACEUTICAL INC is currently very high, coming in at 88.50%. Regardless of BMRN's high profit margin, it has managed to decrease from the same period last year. Despite the mixed results of the gross profit margin, BMRN's net profit margin of -43.52% significantly underperformed when compared to the industry average.
  • BIOMARIN PHARMACEUTICAL INC has experienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, BIOMARIN PHARMACEUTICAL INC continued to lose money by earning -$0.92 versus -$1.29 in the prior year. This year, the market expects an improvement in earnings (-$0.59 versus -$0.92).

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.